Urology News and Research

Latest Urology News and Research

NeoGenomics first-quarter revenue up 22%

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the first quarter 2010.

29 Apr 2010

Watson Laboratories sued in connection with filing of ANDA for generic version of Rapamune tablets

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, has been sued by Pfizer Inc. and Wyeth Pharmaceuticals Inc. in connection with the filing of Watson's Abbreviated New Drug Application for sirolimus tablets in the 1 mg and 2 mg strengths.

29 Apr 2010

Phase I clinical trial results of AE37 in prostate cancer patients presented at EAU Congress

Generex Biotechnology Corporation today announced presentation of additional results from a recently completed Phase I clinical trial of its novel immunotherapeutic peptide AE37 in prostate cancer patients. AE37 is a synthetic cancer vaccine being developed by Antigen Express, Inc., a wholly owned subsidiary of Generex, for multiple cancer indications.

28 Apr 2010

Teleflex' first-quarter 2010 revenues down 1%

Teleflex Incorporated today announced financial results for the first quarter ended March 28, 2010.

27 Apr 2010

Patients with most severe form of prostatitis show signs for periodontitis: Researchers

Researchers from Case Western Reserve University School of Dental Medicine and University Hospitals Case Medical Center report initial results from a small sample that inflammation from gum disease and prostate problems just might be linked. They discuss their new evidence in the Journal of Periodontology, the official journal of the American Academy of Periodontology.

27 Apr 2010

Watson Laboratories sued by Teva Women's Health over generic Cenestin ANDA

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., a Nevada Corporation, has been sued by Teva Women's Health, Inc., in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for synthetic conjugated estrogens, A, in the 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg and 1.25 mg tablet strengths. Watson's ANDA is for the generic equivalent of Teva's Cenestin®. The suit was filed on April 23, 2010, in the United States District Court for the District of New Jersey.

27 Apr 2010

Urigen Pharmaceuticals secures debt held by Platinum-Montaur Life Sciences

Urigen Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced today that the secured debt held by Platinum-Montaur Life Sciences, LLC has been converted into a newly created Series C Preferred Stock of the Company. As a result of the conversion, the lien on the Company's assets, including its intellectual property will be extinguished.

26 Apr 2010

ThermaCor 1200 Rapid Thermal Infusion System used successfully in multiple clinical cases

Smisson-Cartledge Biomedical LLC, an innovator in life saving cardiovascular devices, announced today that its ThermaCor 1200 Rapid Thermal Infusion System has been used successfully in multiple clinical cases in the United States and in the Kingdom of Saudi Arabia.

26 Apr 2010

EDAP announces strategy for ongoing U.S. ENLIGHT Ablatherm-HIFU clinical trial

EDAP TMS SA, the global leader in therapeutic ultrasound, today announced its strategy for the ongoing U.S. ENLIGHT Ablatherm-HIFU clinical trial. Following the FDA Gastroenterology and Urology Devices Panel in December 2009 and the Company's January 2010 meeting with the FDA concerning its recommendations for the trial protocol, the Company has thoroughly evaluated all options aiming at an IDE submission in a feasible timeframe and with acceptable economics.

26 Apr 2010

Investment report featuring Imaging3

MicroStockProfit.com announces an investment report featuring Imaging3 Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

26 Apr 2010

GBS serotype III more commonly associated with urinary tract infections

Research suggests pathogenic strains of Group B Streptococcus (GBS) are an under-recognised cause of urinary tract infections.

24 Apr 2010

Personal risk of developing prostate cancer increases when more direct relatives are affected

For a long time now doctors have known that prostate cancer "runs in the family". Men with family members who have been diagnosed with the disease have an elevated risk of developing cancer of the prostate. But exactly how high is an individual person's risk? For whom and at what age should an early detection screening urgently be recommended?

24 Apr 2010

Urigen Pharmaceuticals requests FDA meeting for advancing URG101 clinical program

Urigen Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced today that it has filed a request for an FDA meeting to advance the URG101 clinical program and mutually agreed with Oceana Therapeutics, Inc. to terminate their Consulting Agreement effective immediately.

24 Apr 2010

City of Manchester, Anthem Blue Cross and Blue Shield enhance Compass SmartShopper Program

Citing strong interest and engagement from city employees as well as requests from school district members, the city of Manchester and Anthem Blue Cross and Blue Shield in New Hampshire announced today enhancements to the innovative Compass SmartShopper Program as well as the addition of Manchester school district employees to the project.

23 Apr 2010

Astellas Pharma extends tender offer for OSI Pharmaceuticals

Astellas Pharma Inc. announced today that it has extended its all-cash tender offer for $52 per share for all of the currently outstanding shares of common stock (including the associated stock purchase rights) of OSI Pharmaceuticals, Inc. to 5:00 p.m. New York City time on Monday, May 17, 2010, unless further extended.

23 Apr 2010

Scientists develop new way of modifying viruses to seek out and destroy cancer cells

CANCER RESEARCH UK scientists at the University of Leeds have developed a new way of modifying viruses to seek out and destroy cancer cells, according to research published in Gene Therapy today1 (Friday).

23 Apr 2010

Study uses new BL-DMAC method to measure PAC levels in cranberry products

Natural compounds in cranberries are linked to the prevention of urinary tract infections (UTIs) but inconsistencies in methods currently used commercially to measure levels can result in the over- or under-estimation of potency levels, leaving product manufacturers and consumers without good data. A study published today in the Journal of the Science of Food and Agriculture outlines a new, commercially viable method of measuring these compounds.

22 Apr 2010

DiagnoCure's proprietary prostate cancer biomarker PCA3 presented at 2010 EAU meeting

DiagnoCure, Inc., a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that its proprietary prostate cancer biomarker PCA3 was the topic of over 13 presentations at the 2010 European Association of Urology meeting, the world largest urology event, held in Barcelona, Spain, with 14,000 registrants.

22 Apr 2010

Gen-Probe's PROGENSA PCA3 assay helps determine necessity of initial biopsy in prostate cancer suspect men

Gen-Probe's PROGENSA® PCA3 assay can help predict the outcome of initial prostate biopsies in men suspected of having prostate cancer, according to a study of the molecular urine test presented in a scientific poster last week at the 25th annual European Association of Urology (EAU) Congress in Barcelona, Spain.

22 Apr 2010

New studies on cancer prevention presented at 101st AACR Annual Meeting 2010

Interest in cancer prevention is increasing as scientists continue to learn new information and confirm what was already suspected.

22 Apr 2010

Urology News and Research

Latest Urology News and Research

NeoGenomics first-quarter revenue up 22%

Watson Laboratories sued in connection with filing of ANDA for generic version of Rapamune tablets

Phase I clinical trial results of AE37 in prostate cancer patients presented at EAU Congress

Teleflex' first-quarter 2010 revenues down 1%

Patients with most severe form of prostatitis show signs for periodontitis: Researchers

Watson Laboratories sued by Teva Women's Health over generic Cenestin ANDA

Urigen Pharmaceuticals secures debt held by Platinum-Montaur Life Sciences

ThermaCor 1200 Rapid Thermal Infusion System used successfully in multiple clinical cases

EDAP announces strategy for ongoing U.S. ENLIGHT Ablatherm-HIFU clinical trial

Investment report featuring Imaging3

GBS serotype III more commonly associated with urinary tract infections

Personal risk of developing prostate cancer increases when more direct relatives are affected

Urigen Pharmaceuticals requests FDA meeting for advancing URG101 clinical program

City of Manchester, Anthem Blue Cross and Blue Shield enhance Compass SmartShopper Program

Astellas Pharma extends tender offer for OSI Pharmaceuticals

Scientists develop new way of modifying viruses to seek out and destroy cancer cells

Study uses new BL-DMAC method to measure PAC levels in cranberry products

DiagnoCure's proprietary prostate cancer biomarker PCA3 presented at 2010 EAU meeting

Gen-Probe's PROGENSA PCA3 assay helps determine necessity of initial biopsy in prostate cancer suspect men

New studies on cancer prevention presented at 101st AACR Annual Meeting 2010

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Urology News and Research

Latest Urology News and Research

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Newsletters you may be interested in